Telitacicept

泰它西普

Report date: 2026/05/08 20:02:52
First In Class

Base Information

Drug NameTelitacicept
Drug Alias NameTaitacept重组人B淋巴细胞刺激因子受体-抗体融合蛋白TaicerceptTeritaceptTelitacept +[11] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator inhibitorsTumor necrosis factor ligand superfamily member 13 inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulatorTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsImmunoglobulin G4-Related DiseaseLupus Erythematosus, SystemicNephrosis +[15] 
Global Approved IndicationsLupus Erythematosus, Systemic
Approved Indications in ChinaLupus Erythematosus, Systemic
Original Approved Country/TerritoryMainland China
Original Approved Date2021/03/09
Country/TerritoryCzechiaBelgiumBulgaria +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRemeGen Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesVor Biopharma IncRemeGen Co Ltd
Inactive CompaniesN/A
Active IndicationsImmunoglobulin G4-Related DiseaseLupus Erythematosus, SystemicNephrosis +[12] 
Inactive IndicationsEye DiseasesMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Other Information

ATC CodeL04AA
Related LinksWikipediaDrugBank